Tuba TASLAMACIOĞLU DUMAN, Selma ERDOĞAN DÜZCÜ, Fahri YILMAZ, Nadire KÜÇÜKÖZTAŞ, Ümmügül ÜYETÜRK

Dermatofibrosarcoma Protuberans: A Rare Malignancy

CONCLUSION As initial treatment, it is important to surgically remove tumors that had no distant metastasis. Positive or near surgical margins should be resected again. If a negative surgical margin cannot be achieved, radiotherapy should be used as the treatment. Imatinib mesylate is used for treatment in unresectable, recurrent, and/or metastatic tumors

PDF

___

1. Eguzo K, Camazine B, Milner D. Giant dermatofibrosarcoma protuberans of the face and scalp: a case report. Int J Dermatol 2014;53(6):767–72.
2. Paramythiotis D, Stavrou G, Panagiotou D, Petrakis G, Michalopoulos A. Dermatofibrosarcoma protuberans: a case report and review of the literature. Hippokratia 2016;20(1):80–3.
3. Trofymenko O, Zeitouni NC. Association of patient demographic characteristics with dermatofibrosarcoma protuberans tumour size at diagnosis in the U.S. National Cancer Database. Br J Dermatol 2017;177(4):e103–4.
4. Wales C, Caravaglio JV, Radi M, Woo R, Bancroft L. A rare case of dermatofibrosarcoma protuberans of the forefoot. Radiol Case Rep 2016;11(2):102–5.
5. Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-Sloan JS, Bordeaux JS. Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States. Dermatol Surg 2016;42 Suppl 1:S24–31.
6. Stamatakos M, Fyllos A, Siafogianni A, Ntzeros K, Tasiopoulou G, Rozis M, et al. Dermatofibrosarcoma protuberans: a rare entity and review of the literature. J BUON 2014;19(1):34–41.
7. Bogucki B, Neuhaus I, Hurst EA. Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg 2012;38(4):537–51.
8. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010;28(10):1772–9.
9. Tsai YJ, Lin PY, Chew KY, Chiang YC. Dermatofibrosarcoma protuberans in children and adolescents: Clinical presentation, histology, treatment, and review of the literature. J Plast Reconstr Aesthet Surg 2014;67(9):1222–9.
10.Loghdey MS, Varma S, Rajpara SM, Al-Rawi H, Perks G, Perkins W. Mohs micrographic surgery for dermatofibrosarcoma protuberans (DFSP): a single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature. J Plast Reconstr Aesthet Surg 2014;67(10):1315–21.
11.Chen YT, Tu WT, Lee WR, Huang YC. The efficacy of adjuvant radiotherapy in dermatofibrosarcoma protuberans: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 2016;30(7):1107–14.
12.Stacchiotti S, Pantaleo MA, Negri T, Astolfi A4 Tazzari M, Dagrada GP, et al. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clin Cancer Res 2016;22(4):837–46.
13.Wang C, Luo Z, Chen J, Zheng B, Zhang R, Chen Y, et al. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients. Medicine (Baltimore) 2015;94(17):e773.
14.Rutkowski P, Klimczak A, Ługowska I, Jagielska B, Wągrodzki M, Dębiec-Rychter M, et al. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. Eur J Surg Oncol 2017;43(6):1134–41.
15.Sellheyer K, Nelson P, Krahl D. Dermatofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem cells? Br J Dermatol 2009;161(6):1317–22.
16.Yan X, Takahara M, Xie L, Tu Y, Furue M. Cathepsin K expression: a useful marker for the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Histopathology 2010;57(3):486–8.
17.Kimmel Z, Alam M. Peripheral excision margins for dermatofibrosarcoma protuberans. Ann Surg Oncol 2008;15(9):2617.
18.Harati K, Lange K, Goertz O, Lahmer A, Kapalschinski N, Stricker I, et al. A single-institutional review of 68 patients with dermatofibrosarcoma protuberans: wide re-excision after inadequate previous surgery results in a high rate of local control. World J Surg Oncol 2017;15(1):5.
19.Flohil SC, van Lee CB, Beisenherz J, Mureau MAM, Overbeek LIH, Nijsten T, et al. Mohs micrographic surgery of rare cutaneous tumours. J Eur Acad Dermatol Venereol 2017;31(8):1285–8.
20.Castle KO, Guadagnolo BA, Tsai CJ, Feig BW, Zagars GK. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 2013;86(3):585–90.